Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,160 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Single Ascending Dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

NCT03858075
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BLU-782, Placebo, BLU-782 taken with food
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
19 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

NCT05983939
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT04596319
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

NCT02620592
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
ZYDPLA1 tablet, Placebo tablet
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 9, 2026, 3:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

NCT06212804
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VIS954, Placebo
Biological · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 9, 2026, 3:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

NCT01262690
View directory record Official record
Conditions
Cachexia
Interventions
PF-05230901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 9, 2026, 3:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

NCT01499017
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 9, 2026, 3:55 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

NCT05279755
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
prosetin, placebo
Drug
Lead sponsor
ProJenX
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

NCT01597947
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ACHN-975, placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768
View directory record Official record
Conditions
Healthy
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906
View directory record Official record
Conditions
Parkinson Disease
Interventions
PDM608, Placebo
Drug
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

NCT06679959
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC30 Injection, for subcutaneous use or placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DISC-3405 in Healthy Volunteers

NCT06050915
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-3405, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

NCT02524782
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MEDI-4166, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Anniston, Alabama • Chula Vista, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

NCT04788017
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ziresovir, Placebo
Drug · Other
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 9, 2026, 3:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

NCT01161082
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
REGN727(SAR236553)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 9, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-7500 in Healthy Adults

NCT06011317
View directory record Official record
Conditions
Healthy Subjects
Interventions
EDG-7500, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 9, 2026, 3:55 PM EDT